Protamine nanoparticles for improving shRNA-mediated anti-cancer effects

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Therapy

Background:

• Apoptosis plays a crucial role in cancer development and progression.
• Targeting anti-apoptotic proteins like Bcl-2 is a promising strategy for cancer therapy.
• Efficient delivery of therapeutic nucleic acids, such as small hairpin RNA (shRNA), remains a challenge in cancer treatment.

Purpose of the Study:

• To develop protamine nanoparticles for encapsulating shRNA targeting the Bcl-2 gene (shBcl-2).
• To evaluate the physicochemical properties and gene protection capabilities of these nanoparticles.
• To assess the in vitro transfection efficiency, cytotoxicity, and apoptosis-inducing effects of shBcl-2 loaded nanoparticles in cancer cells.

Main Methods:

• Protamine nanoparticles were synthesized to encapsulate shBcl-2 plasmid DNA.
• Nanoparticle characterization included particle size, distribution, and surface charge analysis.
• Encapsulation efficiency and protection against DNase I and serum degradation were assessed.
• In vitro transfection efficiency in A549 lung cancer cells was evaluated.
• Cytotoxicity and apoptosis induction were measured after treatment with shBcl-2 loaded nanoparticles.

Main Results:

• Protamine nanoparticles exhibited small particle size, homogenous distribution, and positive charge.
• High encapsulation efficiency for shBcl-2 plasmid DNA was achieved.
• The encapsulated shBcl-2 was protected from enzymatic and serum degradation.
• Significant improvement in shRNA transfection efficiency was observed in A549 cells.
• Enhanced cytotoxicity and increased apoptosis were induced by silencing Bcl-2 via the nanoparticles.

Conclusions:

• Protamine nanoparticles serve as an effective delivery system for shBcl-2.
• This nanocarrier system enhances gene transfection and therapeutic efficacy in cancer cells.
• The developed nanoparticles show potential for improving cancer therapy by targeting apoptosis pathways.